About us

Telara Pharma S.L. is a spin-off company from the Gregorio Marañón Health Research Institute (IiSGM), Gregorio Marañón Universitary General Hospital focused and committed to kidney disease improvement. We are developing a new therapeutic strategy for the treatment of acute kidney injury induced by toxics, sepsis, and sepsis-included acute kidney failure.

The company arises out of the pioneering work on nephroprotection carried out with cilastatin by Dr. Alberto Tejedor Jorge, who recently died from Covid 19, with the intention of fulfilling one of his dreams, to cover a medical need that is not currently covered.


Meet the team

Alberto Lazaro

Alberto Lázaro

Founder & Chief Scientific Officer

PhD in Biochemistry, Molecular Biology and Biomedicine, Universidad Autónoma, Madrid. During his PhD he focused on the search of cellular and molecular mechanisms implicated in renal-cardiovascular diseases. In 2007 he started working as a postdoctoral researcher in the Renal Physiopathology Laboratory, IiSGM-Hospital General Universitario Gregorio Marañón, directed by Dr. Alberto Tejedor, with the main goal of better understanding of cellular and molecular mechanisms of acute kidney injury and its prevention by searching new therapeutic targets and protective strategies. Author of 46 scientific articles published in international journal, h-index of 20, and inventor of 3 patents related to renal damage. He was PI in several competitive national and private projects and supervised 3 doctoral thesis. Since December 2017, he holds a position as assistant professor in the Physiology Department School of Medicine, Complutense University of Madrid.

Amparo Bravo

Amparo Bravo

Founder & Chief Medical Officer

She completed her residency in Family and Community Medicine at Hospital 12 de Octubre (Madrid, Spain). She obtained a PhD in Medicine from the Universidad Autónoma, Madrid, and a Diploma in Public Health from the University of Montreal (Canada). He worked as a postdoctoral Research Fellow in the Department of Pediatrics (Infectious Diseases section) at the Health Science Center (University of Texas, USA). After her stay in NorthAmerica, she worked as a specialist in Family and Community Medicine in Health Area 8, combining her work with resident mentoring at the Fundación Hospital de Alcorcón (Spain), between 2005 and 2013. She currently holds the position of Director of the Palma Universidad Health Center in Madrid (Spain).

Maria Angeles

María Ángeles González-Nicolás

Team member

She has a degree in Biology (specializing in Health Biology) from the Complutense University of Madrid. She began her research career fifteen years ago, during which she has worked in different laboratories such as: the Molecular Diagnostics Laboratory of the Clinical Microbiology Service and the Matrix and Bioartificial Organs Laboratory of the Cardiology Department, both belonging to the Gregorio Marañón Hospital; the Nephrology, Vascular Pathology and Hypertension Laboratory of the IiS-FJD, and in the laboratories of the Nisa Pardo de Aravaca and MD Anderson Spain Hospitals. Since 2015 he has been working in the Renal Physiopathologoy Laboratory at IiSGM-Hospital General Universitario Gregorio Marañón, where she is working on her doctoral thesis oriented to the study of nephroprotection in acute renal failure induced by endotoxic agents.

GENESIS Biomed. Interim CEO.

A consulting company specialised in R + D + i projects in the biomedical sector (www.genesis-biomed.com).
GENESIS supported Gregorio Marañón Hospital Health Research Institute for the creation of Telara Pharma, and essentially, it deals with fundraising and business development.

Josep Luis Falco

Josep Lluís Falcó

Founder and CEO

Doctor in Chemistry (Institut Químic de Sarrià, 2001) and MBA (UB, 2007). View profile

Jordi Ortiz

Jordi Ortiz

Senior Consultant

MSc in Chemistry, Biochemistry field (Universitat de Barcelona). View profile

Berta Tenas

Berta Tenas


BSc in Biotechnology (Universitat de Vic, 2020), and currently studying for a Master’s degree in Management of Biotech Companies from CESIF. View profile

Our partners

We are currently supported by:

Frame 3
Frame 1
Frame 2
Frame 5
Frame 4